Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas

Palbociclib has antitumour effects on Pten- deficient endometrial neoplasias

(2017) Maria Alba Dosil et al.   JOURNAL OF PATHOLOGY

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer

(2017) Tomohito Tanaka et al.   PLoS One

Cyclin D1, cancer progression, and opportunities in cancer treatment

(2016) Shuo Qie et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)

(2016) Sunil Verma et al.   ONCOLOGIST

TCGA Expedition: A Data Acquisition and Management System for TCGA Data

(2016) Uma R. Chandran et al.   PLoS One

CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma

(2016) Atish Mohanty et al.   Oncotarget

Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity

(2015) Matthew T Chang et al.   NATURE BIOTECHNOLOGY

Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management

(2013) Julie M. Vose   AMERICAN JOURNAL OF HEMATOLOGY

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer

(2013) YUJI IKEDA et al.   ONCOLOGY REPORTS

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS